Evidence map›Paper›PMID 40247199›Full record

ReviewBMC psychiatry2025

Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review.

Philip Gorwood, Murat Yildirim, Jessica Madera-McDonough, Andrea Fagiolini, Celso Arango, Christoph U Correll, Emanuele Arcà, Adele Barlassina, Santhani Selveindran, Navdeep Sahota and 1 more

Abstract readReviewConsensus Statement
In one paragraph

Review in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Philip GorwoodInstitute of Psychiatry and Neuroscience of Paris (IPNP), Université Paris Cité, INSERM U1266, Paris, France. p.gorwood@ghu-paris.fr.
Murat YildirimMedical Strategy and Communication, H. Lundbeck A/S, Global Medical Affairs, Copenhagen, Denmark.
Jessica Madera-McDonoughGlobal Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc, Princeton, NJ, USA.
Andrea FagioliniDepartment of Molecular and Developmental Medicine, Division of Psychiatry, Università Di Siena, Siena, Italy.
Celso ArangoChild and Adolescent Department of Psychiatry, Institute of Psychiatry and Mental Health, CIBERSAM, School of Medicine, Hospital General Universitario Gregorio Marañón Universidad Complutense, IiSGM, Madrid, Spain.
Christoph U CorrellDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
Emanuele ArcàPatient-Centered Outcomes, OPEN Health, Rotterdam, The Netherlands.
Adele BarlassinaPatient-Centered Outcomes, OPEN Health, Rotterdam, The Netherlands.
Santhani SelveindranPatient-Centered Outcomes, OPEN Health, Marlow, UK.
Navdeep SahotaAparito Ltd, Wrexham, UK.
John M KaneDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment of schizophrenia has traditionally aimed for symptomatic remission without addressing many daily problems patients face. Although no standard definition of functional recovery in patients with first-episode psychosis (FEP) and early-phase (EP) schizophrenia exists in the literature, most clinicians consider it a useful concept in daily practice. We conducted a Delphi panel to develop expert consensus on assessing functional recovery in FEP and EP schizophrenia patients and defining its domains, which we compared with currently available patient- and clinician-reported outcome measures (PROMs, CROMs).

methodsThe three-stage modified Delphi panel consisted of a 1:1 interview round and two online survey rounds involving five expert steering committee and 16 panel members. We conducted a narrative review of the literature in PubMed to identify instruments assessing functioning in people with schizophrenia.

resultsPanelists were presented with 38 statements about functional recovery (definition, domains, and assessment) and approaches to achieving it. Panelists defined functional recovery for FEP and EP schizophrenia patients as a multidimensional state closely related to quality of life. When evaluating functional recovery, panelists agreed that assessing (1) depression, (2) aggressive behavior, (3) social interaction, (4) family functioning, (5) education and/or employment, (6) leisure activities, (7) self-care, and (8) sexual functioning was important. Panelists also agreed that asking patients about self-care and sexual functioning was less critical at every encounter. It was agreed that patients may be said to have reached partial functional recovery if they recovered in some but not all domains. There was consensus that long-acting injectable antipsychotics can facilitate functional recovery by increasing treatment adherence, lessening disease and treatment burden, and reducing functional decline. The literature review identified eight PROMs and CROMs that assess functioning in schizophrenia. However, none evaluated all eight domains of functional recovery.

conclusionsFunctional recovery is an important treatment goal in FEP and EP patients. PROMs and CROMs do not evaluate all eight domains of functional recovery agreed by the Delphi panel. Further research is needed to better understand and improve how functional recovery is assessed in clinical practice.

Indexed as

Outcome Assessment, Health CarePsychotic DisordersRecovery of FunctionSchizophreniaSchizophrenic PsychologyDelphi TechniqueHumansQuality of LifeAntipsychoticsClinical consensusDelphi panelEarly-phase schizophreniaFirst-episode psychosisFunctional recoveryLong-acting injectablePatient-reported outcome measuresRecommendationsSchizophrenia

Identifiers

PMID40247199
PMCPMC12007312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.